Goldman Sachs analyst Asad Haider has maintained their bullish stance on LLY stock, giving a Buy rating yesterday.
Asad Haider has given his Buy rating due to a combination of factors that highlight Eli Lilly & Co.’s potential for growth and market leadership. The recent decline in stock price presents an attractive entry point into a company recognized as a leader in topline growth within the sector. Haider’s analysis emphasizes Eli Lilly’s strong position in the anti-obesity medication market, which is expected to expand significantly in the coming years. The company’s manufacturing capabilities, early-mover advantage, and comprehensive cardiometabolic portfolio are seen as key strengths that will enable it to maintain its leadership as the market grows.
Additionally, Haider points to Eli Lilly’s strategic approach to replicating its success in the obesity/incretin franchise across its broader portfolio. The company’s focus on large markets and its efforts to accelerate the timeline to monetization are expected to drive new product cycles and create value well before facing any major patent expirations. These factors collectively underpin Haider’s confidence in Eli Lilly’s long-term growth prospects, supporting the Buy rating.
According to TipRanks, Haider is a 2-star analyst with an average return of 3.0% and a 33.33% success rate.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $1,190.00 price target.